Is treatment of hepatitis C with controlled generic direct acting antiviral drugs effective? An Egyptian experience

2018 ◽  
Vol 68 ◽  
pp. S276 ◽  
Author(s):  
G. Soliman ◽  
M.S. Negm ◽  
M. Elzalabany ◽  
A.A. Malik ◽  
A. Khattab ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Antiviral Drugs ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Hepatitis C Virus Infection and Renal Disorders

2019 ◽  
Vol 3 (1) ◽  
pp. 1-14
Author(s):  
Maurizio Salvadori ◽  
Aris Tsalouchos
Keyword(s):  
Hepatitis C Virus ◽  
Renal Transplantation ◽  
Hepatitis C ◽  
Sustained Virologic Response ◽  
Virologic Response ◽  
Antiviral Drugs ◽  
Renal Diseases ◽  
Renal Disorders ◽  
Direct Acting Antiviral ◽  
Direct Acting

Hepatitis C virus (HCV) infection is frequently associated with extrahepatic disorders, among which renal diseases are frequent. This article highlights the most frequent HCV-associated renal disorders, the impact of HCV infection on chronic renal disease and renal transplantation, and the role of current direct-acting antiviral therapies. HCV is associated with membranoproliferative glomerulonephritis, acceleration of end-stage renal diseases in patients with glomerulopathies, and a higher risk of death in patients affected by chronic kidney disease. Before the introduction of direct-acting antiviral drugs as treatment modality, renal transplantation was a challenging clinical problem because the drugs available until 2011 obtained a poor sustained virologic response, had several side effects, and caused acute rejection when used after transplantation. The knowledge of the viral structure and its replication allowed the discovery of new classes of direct-acting antiviral drugs that revolutionized this scenario. These new drugs are comparatively more effective and safer. Accumulating evidence suggests that it is possible to cure HCV-related glomerulonephritis, and obtain a sustained virologic response in patients with renal failure, or on dialysis, before commencing transplantation. Finally, it became possible to transplant HCV-positive kidneys into HCV-positive or HCV-negative recipients.

Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review

2018 ◽  
Vol 13 (5) ◽  
pp. 775-790 ◽  
Author(s):  
Eleonora Tamborini Permunian ◽  
Lorenzo Gervaso ◽  
Victor Gerdes ◽  
Lorenzo Moja ◽  
Luigina Guasti ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Drugs ◽  
Vascular Events ◽  
Direct Acting Antiviral ◽  
Direct Acting

Safety and Efficacy of Direct-Acting Antiviral Drugs in Patients with Haemoglobinophaties and Chronic Hepatitis C Infection

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3627-3627
Author(s):  
Antonio Piga ◽  
Paolo Rigano ◽  
Raffaella Origa ◽  
M. Domenica Cappellini ◽  
Valeria Pinto ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Research Funding ◽  
Antiviral Drugs ◽  
Post Treatment ◽  
Safety And Efficacy ◽  
Direct Acting Antiviral ◽  
Co Morbidity ◽  
Direct Acting

Abstract Background and Aim: Direct-acting antiviral drugs (DAAs) have a very high efficacy in patients with hepatitis C virus (HCV) infection, but they have not been extensively used in patients with haemoglobinophaties. To evaluate the safety and efficacy of DAA regimens in this subset we used the ITHACA-SITE dataset, which includes patients with haemoglobinophaties and chronic HCV liver disease treated in Italy. Patients and methods: Between March 2015 and June 2016, 121 patients included in the ITHACA-SITE dataset started DAA regimens. Cirrhosis was defined by FibroScan®showing≥12 kPa performed within 6 months before the treatment. Regimen choice and use of ribavirin were based on viral genotype and stage of disease, according to guidelines. Negative HCV RNA at week 12 of post-treatment follow up was considered as Sustained Virological Response (SVR). Results: The mean age of 121 patients was 42 years, 75 (62%) were males, 101 (83.5%) had β-thalassemia major, 9(7.5%) had β-thalassemia intermedia and 10 (8.3%) had sickle cell disease. Sixty-six patients (54%) had the diagnosis of chronic hepatitis and 55 (46%) hadthe diagnosis of cirrhosis. The prevalence of HCV genotypes (G) was: G1a 6 (5%), G1b 70 (57.8%), G2 31 (25.6%), G3 6 (5%), G4 8 (6.6%). Fifty-six patients (46.3%) were Peg-interferon (P) and Ribavirin (R) naïve and 65 (53.7%) were P/R experienced, 20 patients (16.5%) had diabetes and 29 (24%) had heart disease. By June 2016 63 patients (52%) had concluded the treatment and 33 (27.3%) had concluded the post-treatment follow-up. By ITT, the rate of response at the end of treatment (ETR) was 100% (63/63) and 94% (31/33) of patients achieved a SVR. No patients stopped treatment because of adverse events. No interference with chelation therapy was observed. Conclusions: Use of DAAs regimens in practice is safe and effective in patients with haemoglobinophaties and cirrhosis or chronic hepatitis due to HCV. The therapy is indicated also in patients with co-morbidity. The lifetime utility of HCV eradication in terms of reduction of events and overall survival needs evaluation in long-term observational cohorts. Disclosures Piga: Novartis: Research Funding; Apopharma: Honoraria. Di Marco:Gilead: Research Funding. Forni:Novartis, Celgene: Research Funding.

Diagnosis of chronic hepatitis C in the era of direct-acting antiviral drugs

2019 ◽  
Vol 17 (4) ◽  
pp. 62-68
Author(s):  
S.N. Batskikh ◽  
◽  
V.P. Chulanov ◽  
V.I. Pokrovskiy ◽  
◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Drugs ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals History and progress of antiviral drugs: From acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C

2015 ◽  
Vol 17 (68) ◽  
pp. 165-174 ◽  
Author(s):  
O.L. Bryan-Marrugo ◽  
J. Ramos-Jiménez ◽  
H. Barrera-Saldaña ◽  
A. Rojas-Martínez ◽  
R. Vidaltamayo ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Antiviral Agents ◽  
Antiviral Drugs ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents
Sign in / Sign up

Export Citation Format

Share Document